FY2024 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($4.72) per share for the year, up from their previous estimate of ($4.77). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.72) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.05) EPS, FY2025 earnings at ($4.30) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $4.15 EPS and FY2028 earnings at $10.10 EPS.

Several other equities analysts have also commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Robert W. Baird boosted their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Finally, Truist Financial lifted their price target on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $132.08.

Axsome Therapeutics Trading Down 2.2 %

Shares of AXSM opened at $106.46 on Friday. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $111.51. The company has a market capitalization of $5.16 billion, a PE ratio of -16.30 and a beta of 1.04. The stock has a fifty day moving average of $93.57 and a two-hundred day moving average of $90.81. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the business posted ($1.32) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Iron Triangle Partners LP acquired a new position in Axsome Therapeutics during the 3rd quarter worth $22,671,000. Principal Financial Group Inc. lifted its holdings in Axsome Therapeutics by 6,002.7% in the fourth quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock worth $17,520,000 after purchasing an additional 203,672 shares during the period. FMR LLC grew its position in Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after buying an additional 185,951 shares in the last quarter. abrdn plc increased its stake in Axsome Therapeutics by 553.3% during the 4th quarter. abrdn plc now owns 72,179 shares of the company’s stock valued at $6,107,000 after buying an additional 61,131 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Axsome Therapeutics by 47.5% in the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock worth $13,713,000 after acquiring an additional 51,696 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.